Not an accelerator! We build with you.
IKP ARK embeds operators into your startup to turn deep science into a fundable, Series A–ready company.
IKP ARK is a venture a program for deep-science startups in MedTech and HealthTech - taking you from working proof-of-conept to a monetisable, fundable company through embedded operators and disciplined execution. This is not an incubator, grant program, or pitch platform. ARK is a structured, time-bound system where operators are accountable alongside founders—built on evidence, not opinions, and execution, not promises.
A co-building partnership where IKP’s operator team (Black Belts) is embedded inside your venture—retiring every commercial risk from productization to regulatory to fundraising.
Imminent industry leaders, rigorous academics, and seasoned deep-tech entrepreneurs — handpicked by IKP leadership for each venture's specific domain and phase. The right people, for the right problem, at the right time.
A dedicated team of operators, domain experts, and leaders committed to your venture's success.
Structured as a 12-month, 3-phase program. IKP equity is milestone-vested - earned through capital, execution, and co-building.
IKP leads structured diagnostic interviews across all 7 stack elements — every gap named, every risk scored (Days 1–2). Then roadmap building domain by domain, led by IKP’s embedded specialists (Days 3–5). Day 6 is Blueprint Day: both parties sign the Venture Blueprint and commit to Phase 2 — or part ways cleanly.
The most intensive sustained phase. Every stack element attacked in focused micro-sprints until the risk is retired. Weekly PMU/Operations team sessions — milestone scorecard, blockers, commitments, IKP action items.
Founders lead. IKP shifts to a strategic embedded partner with capital at stake—aligned for outcomes. IKP opens up manufacturing, regulatory, and clinical infrastructure. Post 12 months, IKP has the option to invest further.
Up to ₹ 1 Cr per startup, deployed milestone by milestone. Not a blanket cheque — capital earned against defined progress.
Embedded in your venture. CDSCO, FSSAI, biosafety, clinical validation strategy.
Shreyas Kuduva embedded sprint-by-sprint. DFM review, supply chain mapping, vendor qualification.
GTM hypothesis, fundraising narrative, business model — all stress-tested by the PMU team.
IKP’s 20+ year network of research institutions, clinical partners, industry collaborators, and investors
SmartFab infrastructure access, IP/legal/finance support, and best-in-class mentors.
"Deep science fails not because of weak science. It fails because the path from lab to market is fragmented and poorly supported" — THE IKP ARK THESIS
If your science is ready and you're committed to building a company — not continuing research.
Contact Aaqib Jameel (Programme Lead) directly — we respond to every serious inquiry.
Formal open call published following the April 2026 launch event via IKP's website.